Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	KIT exon 11 del
Gene Variant Detail	KIT exon 11 del (gain of function)
Relevant Treatment Approaches	KIT Inhibitor

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 16 of 16 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	KIT Inhibitor	Imatinib	Phase III	Actionable	In a Phase III trial, gastrointestinal stromal tumor patients harboring KIT exon 11 deletions or indels demonstrated improved recurrence-free survival (RFS) with 3-year adjuvant Gleevec (imatinib) treatment (5-year RFS, 70%), compared to patients receiving 1-year treatment (5-year RFS, 41.3%) (PMID: 28334365).	28334365
KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	KIT Inhibitor	Imatinib	Phase III	Actionable	In a Phase III trial, 3-year adjuvant Gleevec (imatinib) treatment resulted in an improved 10-year overall survival rate (86% vs 64%, HR=0.34, p=0.0007) and 10-year recurrence-free survival rate (47% vs 29%, HR=0.48, p<0.001) compared to 1-year adjuvant treatment in patients with gastrointestinal stromal tumors harboring KIT exon 11 deletion or indel mutations (PMID: 37014660; NCT00116935).	37014660
KIT exon 11 del	acral lentiginous melanoma	predicted - sensitive	KIT Inhibitor	Nilotinib	Case Reports/Case Series	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in an overall response rate of 16.7% (7/42, 1 complete and 6 partial responses) and a disease control rate of 57.1% in melanoma patients harboring KIT mutations (n=25), amplification (n=15), or both (n=2), including a partial response with a duration of response of 13 weeks in a patient with acral melanoma harboring a KIT exon 11 deletion (PMID: 26424760; NCT01099514).	26424760
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Ripretinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Qinlock (ripretinib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion, resulted in tumor regression in cell line xenograft models (PMID: 31085175).	31085175
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Avapritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ayvakit (avapritinib) inhibited cell growth and induced cell cycle arrest in gastrointestinal stromal tumor cells harboring a KIT exon 11 deletion in culture, and inhibited tumor growth and led to prolonged survival in cell line xenograft models (PMID: 33320833).	33320833
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Adavosertib + Avapritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Adavosertib (MK-1775) and Ayvakit (avapritinib) demonstrated an additive effect on inhibiting cell growth and inducing apoptosis in gastrointestinal stromal tumor cells harboring a KIT exon 11 deletion in culture, and inhibited tumor growth and led to prolonged survival in cell line xenograft models (PMID: 33320833).	33320833
KIT exon 11 del	gastrointestinal stromal tumor	no benefit		Adavosertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Adavosertib (MK-1775) treatment resulted in reduced cell viability of gastrointestinal stromal tumor cells harboring a KIT exon 11 deletion in culture, but did not lead to improved tumor growth inhibition or prolonged survival compared to controls in cell line xenograft models (PMID: 33320833).	33320833
KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	KIT Inhibitor	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	KIT Inhibitor	THE-630	Preclinical - Cell culture	Actionable	In a preclinical study, THE-630 treatment inhibited cell viability and KIT signaling in a gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1292).	detail...
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Qinlock (ripretinib) inhibited viability of a gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion in culture (PMID: 38408285).	38408285
KIT exon 11 del	gastrointestinal stromal tumor	sensitive	KIT Inhibitor	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited viability of a gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion in culture (PMID: 38408285).	38408285
KIT exon 11 del	gastrointestinal stromal tumor	sensitive		Nintedanib	Preclinical - Cell culture	Actionable	In a preclinical study, Ofev (nintedanib) inhibited viability of a gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion in culture (PMID: 38408285).	38408285

Showing 1 to 16 of 16 entries

Filter rows: